Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Ligand Pharmaceuticals
Deal Size : $128.0 million
Deal Type : Acquisition
Ligand to Acquire APEIRON Biologics AG for $100 Million
Details : Ligand acquires Apeiron Biologics pipeline which also includes Qarziba (dinutuximab beta), it is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above.
Brand Name : Qarziba
Molecule Type : Large molecule
Upfront Cash : $100.0 million
July 08, 2024
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Ligand Pharmaceuticals
Deal Size : $128.0 million
Deal Type : Acquisition
Lead Product(s) : Alunacedase Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
APEIRON Respiratory Therapies Announces Positive Results From Phase I Trial of Inhaled APN01
Details : The study met all primary and secondary endpoints, with all results indicating that the inhalation of APN01 (alunacedase alfa) at all dosage levels used in the trial is safe and well tolerated.
Brand Name : APN01
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 02, 2022
Lead Product(s) : Alunacedase Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Alunacedase Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Apeiron Biologics Begins Phase 1 Trial to Treat Covid-19 with Inhaled APN01
Details : Primary study objective is the evaluation of safety and tolerability of single ascending doses (SADs) and multiple ascending doses (MADs) of inhaled APN01 when administered via a jet nebulizer in healthy subjects.
Brand Name : APN01
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 12, 2021
Lead Product(s) : Alunacedase Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BNC210
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Recipient : Bionomics
Deal Size : Undisclosed
Deal Type : Financing
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial
Details : Under the Subscription Agreement dated 2 June 2020 with Apeiron, Apeiron agreed to recapitalise the Company and assist in securing further equity capital to fund the Company's BNC210 Phase 2b Clinical trial for the treatment of post-traumatic stress diso...
Brand Name : BNC210
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 10, 2021
Lead Product(s) : BNC210
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Recipient : Bionomics
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : SNS-301,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Sensei Biotherapeutics
Deal Size : $30.0 million
Deal Type : Series B Financing
Details : Sensei’s lead ImmunoPhage product candidate, SNS301, is being evaluated in a Phase 1/2 trial for the treatment of locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.
Brand Name : SNS-301
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 11, 2021
Lead Product(s) : SNS-301,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Sensei Biotherapeutics
Deal Size : $30.0 million
Deal Type : Series B Financing
Expansion of APEIRON Biologics and Domainex Partnership will Advance Cancer Drug Discovery
Details : Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.
Brand Name : APN431
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 09, 2020
Lead Product(s) : Alunacedase alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial.
Brand Name : APN01
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 25, 2020
Lead Product(s) : Alunacedase alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
APEIRON Biologics and MaxCyte Enter Into Clinical and Commercial Licensing Agreement for APN401
Details : Under the terms of this licensing agreement, APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials.
Brand Name : APN401
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 07, 2020
Lead Product(s) : APN01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Apeiron Biologics gets regulatory approvals for Phase II Covid-19 trial
Details : Regulatory approvals obtained for the treatment of 200 COVID-19 patients in Austria, Germany and Denmark; Austrian government to provide significant financial support.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 02, 2020
Lead Product(s) : APN01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : APN01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The randomized, unblinded trial will treat 24 patients for seven days to obtain preliminary data on the impact of rhACE2 on biological, physiologic, and clinical outcomes and safety in patients.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 26, 2020
Lead Product(s) : APN01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?